首页> 外文期刊>International Journal of Pharmaceutics >Evaluation of critical formulation parameters in design and differentiation of self-microemulsifying drug delivery systems (SMEDDSs) for oral delivery of aciclovir
【24h】

Evaluation of critical formulation parameters in design and differentiation of self-microemulsifying drug delivery systems (SMEDDSs) for oral delivery of aciclovir

机译:在设计和区分用于口服阿昔洛韦的自微乳化药物递送系统(SMEDDS)中评估关键配方参数

获取原文
获取原文并翻译 | 示例
           

摘要

The study investigated the influence of formulation parameters for design of self-microemulsifying drug delivery systems (SMEDDSs) comprising oil (medium chain triglycerides) (10%), surfactant (Labrasol (R), polysorbate 20, or Kolliphor (R) RH40), cosurfactant (Plurol (R) Oleique CC 497) (q.s. ad 100%), and cosolvent (glycerol or macrogol 400) (20% or 30%), and evaluate their potential as carriers for oral delivery of a poorly permeable antivirotic aciclovir (acyclovir). The drug loading capacity of the prepared formulations ranged from 0.18-31.66 mg/ml. Among a total of 60 formulations, three formulations meet the limits for average droplet size (Z-ave) and polydispersity index (PdI) that have been set for SMEDDSs (Z-ave <= 100 nm, PdI < 0.250) upon spontaneous dispersion in 0.1 M HCl and phosphate buffer pH 7.2. SMEDDSs with the highest aciclovir loading capacity (24.06 mg/ml and 21.12 mg/ml) provided the in vitro drug release rates of 0.325 mg cm (2) min (1) and 0.323 mg cm (2) min (1), respectively, and significantly enhanced drug permeability in the parallel artificial membrane permeability assay (PAMPA), in comparison with the pure drug substance. The results revealed that development of SMEDDSs with enhanced drug loading capacity and oral delivery potential, required optimization of hydrophilic ingredients, in terms of size of hydrophilic moiety of the surfactant, surfactant-to-cosurfactant mass ratio (Km), and log P of the cosolvent. (C) 2015 Elsevier B.V. All rights reserved.
机译:该研究调查了配方参数对设计自微乳化药物递送系统(SMEDDS)的影响,该系统包含油(中链甘油三酸酯)(10%),表面活性剂(Labrasol(R),聚山梨酸酯20或Kolliphor(R)RH40),助表面活性剂(Plurol(R)Oleique CC 497)(qs ad 100%)和助溶剂(甘油或聚乙二醇400)(20%或30%),并评估其作为口服药物的潜力,可用于口服递送渗透性较差的抗病毒药阿昔洛韦(acyclovir) )。制备的制剂的载药量为0.18-31.66mg / ml。在总共60种配方中,三种配方满足自发分散在SMEDDSs(Z-ave <= 100 nm,PdI <0.250)时对平均液滴尺寸(Z-ave)和多分散指数(PdI)的限制。 0.1 M HCl和磷酸盐缓冲液pH 7.2。阿昔洛韦负载量最高的SMEDDSs(24.06 mg / ml和21.12 mg / ml)分别提供0.325 mg cm(2)min(1)和0.323 mg cm(2)min(1)的体外药物释放速率,与纯药物相比,在平行人工膜通透性试验(PAMPA)中显着提高了药物的通透性。结果表明,开发具有更高载药量和口服递送潜力的SMEDDS,需要优化亲水性成分,包括表面活性剂亲水部分的大小,表面活性剂与助表面活性剂的质量比(Km)和log P助溶剂。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号